<html>
<head>
<title>Form 8-K
</title>
</head>
<body>




<hr size=3 noshade>

<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br></b></font>
<font face="Times New Roman, Times, Serif" size=2>Washington, DC 20549</font>
</p>

<hr width=25% noshade>

<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>FORM 8-K<br>
<br></b></font></p>
<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>CURRENT REPORT</b></font><br><font face="Times New Roman, Times, Serif" size=2><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934<br></b></font></p>
<p align=center>
<font face="Times New Roman, Times, Serif" size=2>Date of Report&nbsp;&nbsp;(Date of earliest event reported):&nbsp;&nbsp;&nbsp;&nbsp;January 5, 2006</font><br></p>
<hr width=25% noshade>
<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>MILLENNIUM PHARMACEUTICALS, INC.</b></font><br><font face="Times New Roman, Times, Serif" size=2>(Exact name of registrant as specified in its charter)</font></p>
<table width=100% border=0 cellpadding=0 cellspacing=0 align=center>

<tr>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>Delaware</b></font></td>
<td width=34% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>0-28494</b></font></td>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>04-3177038</b></font></td>
</tr>
<tr>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(State or other jurisdiction<br>of incorporation)</font></td>
<td width=34% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(Commission file number)</font></td>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(IRS&nbsp;Employer<br>Identification&nbsp;No.)</font></td>
</tr>




</table>


<p align=center><font face="Times New Roman, Times, Serif" size=2><b>40 Landsdowne Street<br>Cambridge, Massachusetts 02139</b><br>
(Address of principal executive offices)&nbsp;(zip code)</font></p>

<p align=center><font face="Times New Roman, Times, Serif" size=2><b>(617)&nbsp;&nbsp;679-7000<br></b>
(Registrant's telephone number, including area code)</font></p>

<p align=center><font face="Times New Roman, Times, Serif" size=2><b>Not applicable<br></b>
(Former name or former address if changed since last report)</font></p>

<p align=left><font face="Times New Roman, Times, Serif" size=2>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></p>

<table width=100% border=0 cellpadding=0 cellspacing=0>

<tr>
<td align=right valign=top width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top width=1%><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top width=2%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=top width=94%><font face="Times New Roman, Times, Serif" size=2>Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>

</table>




<hr size=3 noshade width=100%>

<table border=0 cellpadding=0 cellspacing=0>
<tr valign=top>

<td width=9%><font face="Times New Roman, Times, Serif" size=2><b>Item&nbsp;&nbsp;&nbsp;2.02</b></font></td>
<td width=3%>&nbsp;</td>
<td width=68% align=left><font face="Times New Roman, Times, Serif" size=2><b>Results of Operations and Financial Condition.</b></font></td>
<td width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>

</table>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On January 5, 2006, Millennium
Pharmaceuticals, Inc. issued a press release to report selected unaudited financial
results for the year ended December 31, 2005 and to provide information about its goals
for 2006. The full text of the press release is attached to this Current Report on Form
8-K as Exhibit 99.1. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The information in this Form 8-K
shall not be deemed &#147;filed&#148; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &#147;Exchange Act&#148;) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The attached press release contains
non-GAAP financial measures. These non-GAAP measures should be considered in addition to,
not as a substitute for, or superior to other measures of the Company&#146;s financial
position prepared in accordance with generally accepted accounting principles (GAAP). </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Specifically, the attached press
release discusses non-GAAP net income and non-GAAP profitability, which are non-GAAP
financial measures. With respect to forward-looking
information presented on a non-GAAP basis, other than amortization expenses of
approximately $34 million in each of 2005 and 2006, restructuring charges of between $80
million and $85 million in 2005 and between $25 million and $30 million in 2006 and stock
based compensation expense of between $40 million and $50 million in 2006, the Company is
unable to provide a quantitative reconciliation because the items that would be excluded
are difficult to predict and estimate and are primarily dependent on future events. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The Company&#146;s management uses
these non-GAAP financial measures to gain a better understanding of the Company&#146;s
core operating results and future prospects, consistent with how management measures and
forecasts the Company&#146;s performance, especially when comparing such results to
previous periods or forecasts or to those of the Company&#146;s competitors. These
measures are also used by the Company&#146;s management in their financial and operating
decision-making and for compensation purposes.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>These non-GAAP measures exclude certain
non-operational and restructuring charges, non-cash charges and specified other charges
that are included in the most directly comparable GAAP measures. The Company excludes
these items because it believes they are outside of the Company&#146;s normal operations
and, in certain cases, are difficult to forecast accurately for future periods.
Specifically, on both a historic and a forward-looking basis, these non-GAAP measures
exclude: </FONT></P>



<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;
Costs associated with the Company&#146;s 2005 strategic refinement and restructuring, such as reducing overhead and
consolidating facilities, resulting from the restructured relationship between
Schering-Plough and the Company for INTEGRILIN&reg; (eptifibatide) Injection and the
reduction in the Company&#146;s inflammation discovery programs. The Company believes that
the costs related to these restructuring activities are not indicative of the
Company&#146;s normal operating costs. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;
Costs associated with the Company&#146;s 2003 restructuring effort, such as reducing overhead and consolidating
facilities. The Company believes that the costs related to these restructuring activities
are not indicative of the Company&#146;s normal operating costs.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;
Expense associated with the amortization of acquisition-related intangible assets because a significant portion of the
purchase price for acquisitions may be allocated to intangible assets that have lives of
two to 13 years. Exclusion of the amortization expense allows comparisons of operating
results that are consistent over time for both the Company&#146;s newly acquired and
long-held businesses and with both acquisitive and non-acquisitive peer companies.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;
Costs associated with the Company&#146;s debt financing activities such as amortization on capitalized professional
and banking fees and charges related to the fair value of the put premiums the Company has</FONT></P>

<p align=center><font face="Times New Roman, Times, Serif" size=2>2</font></p>
<hr size=3 noshade>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>placed on its convertible notes because the Company considers these costs to be
nonoperational and nonrecurring and therefore not necessarily indicative of the
Company&#146;s future financial commitments.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;
Expense associated with stock-based compensation related to stock options, the Company&#146;s employee stock purchase plan and
restricted stock because the Company believes that including this expense could be
misleading in the comparison of the Company&#146;s financial results to previous periods
and does not provide meaningful insight into the Company&#146;s ongoing operations.
Additionally, because of varying available valuation methodologies, subjective assumptions
and the variety of award types, the Company believes that the inclusion of stock-based
compensation could create the potential for misleading comparisons of the Company&#146;s
operating results to its competitors.</FONT></P>




<p align=left><font face="Times New Roman, Times, Serif" size=2><b>Item&nbsp;&nbsp;&nbsp;&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statements and Exhibits.</b></font></p>

<table border=0 cellpadding=0 cellspacing=0>
<tr>
<td align=left width=20%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left width=10%><font face="Times New Roman, Times, Serif" size=2>(c)</font></td>
<td align=left width=70%><font face="Times New Roman, Times, Serif" size=2>Exhibits</font></td>
</tr>
<tr>
<td align=left width=20%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=10%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left width=70%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td width=20%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=10%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=70%><font face="Times New Roman, Times, Serif" size=2>See Exhibit Index attached to this Current Report on Form 8-K.</font></td>
</tr>
<tr>
<td align=left width=20%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=10%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left width=70%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>

</table>

<p align=center><font face="Times New Roman, Times, Serif" size=2>3</font></p>
<hr size=3 noshade>




<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2><b><a name="sig">SIGNATURE</a></b></font></p>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.</font></p>




<table border=0 cellpadding=0 cellspacing=0>
<tr valign=bottom>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td colspan=2><font face="Times New Roman, Times, Serif" size=2>MILLENNIUM PHARMACEUTICALS, INC.<br>(Registrant)<br><br></font></td>
</tr>
<tr valign=bottom>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>Date: January 5, 2006&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>By&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>/s/&nbsp;&nbsp;MARSHA H. FANUCCI</font></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2></font><hr noshade></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>Marsha H. Fanucci</font></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>Senior Vice President and Chief Financial Officer</font></td>
</tr>
</table>




<p align=center><font face="Times New Roman, Times, Serif" size=2>4</font></p>
<hr noshade size=3>




<p><font face="Times New Roman, Times, Serif" size=2><b>EXHIBIT INDEX</b></font></p>

<table border=0 cellpadding=0 cellspacing=0>
<tr valign=bottom>
<th width=9% align=center colspan=2><font face="Times New Roman, Times, Serif" size=2>Exhibit No.<br></font><hr noshade></th>
<th width=3%>&nbsp;</th>
<th width=68% align=center><font face="Times New Roman, Times, Serif" size=2>Description<br></font><hr noshade></th>
<th width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></th>
</tr>
<tr valign=top>
<td width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=6%><font face="Times New Roman, Times, Serif" size=2>99.1</font></td>
<td width=3%>&nbsp;</td>
<td width=68% align=left><font face="Times New Roman, Times, Serif" size=2>Press Release of Millennium Pharmaceuticals, Inc. dated January 5, 2006</font></td>
<td width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr valign=top>
<td width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=6%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=3%>&nbsp;</td>
<td width=68% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
</table>




<p align=center><font face="Times New Roman, Times, Serif" size=2>5</font></p>





















</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "fm8k01052006.htm", "description": "FORM 8-K", "secsgml_size_bytes": 19100}]
{"company-data": {"conformed-name": "MILLENNIUM PHARMACEUTICALS INC", "cik": "0001002637", "assigned-sic": "2834", "irs-number": "043177038", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28494", "film-number": "06513488"}, "business-address": {"street1": "40 LANDSDOWNE STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02139", "phone": "6176797000"}, "mail-address": {"street1": "40 LANDSDOWNE STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02139"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report  (Date of earliest event reported):    January 5, 2006
MILLENNIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
0-28494
04-3177038
(State or other jurisdiction
of incorporation)
(Commission file number)
(IRS Employer
Identification No.)
40 Landsdowne Street
Cambridge, Massachusetts 02139
(Address of principal executive offices) (zip code)
(617)  679-7000
(Registrant's telephone number, including area code)
Not applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item   2.02
Results of Operations and Financial Condition.
On January 5, 2006, Millennium
Pharmaceuticals, Inc. issued a press release to report selected unaudited financial
results for the year ended December 31, 2005 and to provide information about its goals
for 2006. The full text of the press release is attached to this Current Report on Form
8-K as Exhibit 99.1.
The information in this Form 8-K
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.
The attached press release contains
non-GAAP financial measures. These non-GAAP measures should be considered in addition to,
not as a substitute for, or superior to other measures of the Company's financial
position prepared in accordance with generally accepted accounting principles (GAAP).
Specifically, the attached press
release discusses non-GAAP net income and non-GAAP profitability, which are non-GAAP
financial measures. With respect to forward-looking
information presented on a non-GAAP basis, other than amortization expenses of
approximately $34 million in each of 2005 and 2006, restructuring charges of between $80
million and $85 million in 2005 and between $25 million and $30 million in 2006 and stock
based compensation expense of between $40 million and $50 million in 2006, the Company is
unable to provide a quantitative reconciliation because the items that would be excluded
are difficult to predict and estimate and are primarily dependent on future events.
The Company's management uses
these non-GAAP financial measures to gain a better understanding of the Company's
core operating results and future prospects, consistent with how management measures and
forecasts the Company's performance, especially when comparing such results to
previous periods or forecasts or to those of the Company's competitors. These
measures are also used by the Company's management in their financial and operating
decision-making and for compensation purposes.
These non-GAAP measures exclude certain
non-operational and restructuring charges, non-cash charges and specified other charges
that are included in the most directly comparable GAAP measures. The Company excludes
these items because it believes they are outside of the Company's normal operations
and, in certain cases, are difficult to forecast accurately for future periods.
Specifically, on both a historic and a forward-looking basis, these non-GAAP measures
exclude:
•
Costs associated with the Company's 2005 strategic refinement and restructuring, such as reducing overhead and
consolidating facilities, resulting from the restructured relationship between
Schering-Plough and the Company for INTEGRILIN® (eptifibatide) Injection and the
reduction in the Company's inflammation discovery programs. The Company believes that
the costs related to these restructuring activities are not indicative of the
Company's normal operating costs.
•
Costs associated with the Company's 2003 restructuring effort, such as reducing overhead and consolidating
facilities. The Company believes that the costs related to these restructuring activities
are not indicative of the Company's normal operating costs.
•
Expense associated with the amortization of acquisition-related intangible assets because a significant portion of the
purchase price for acquisitions may be allocated to intangible assets that have lives of
two to 13 years. Exclusion of the amortization expense allows comparisons of operating
results that are consistent over time for both the Company's newly acquired and
long-held businesses and with both acquisitive and non-acquisitive peer companies.
•
Costs associated with the Company's debt financing activities such as amortization on capitalized professional
and banking fees and charges related to the fair value of the put premiums the Company has
2
placed on its convertible notes because the Company considers these costs to be
nonoperational and nonrecurring and therefore not necessarily indicative of the
Company's future financial commitments.
•
Expense associated with stock-based compensation related to stock options, the Company's employee stock purchase plan and
restricted stock because the Company believes that including this expense could be
misleading in the comparison of the Company's financial results to previous periods
and does not provide meaningful insight into the Company's ongoing operations.
Additionally, because of varying available valuation methodologies, subjective assumptions
and the variety of award types, the Company believes that the inclusion of stock-based
compensation could create the potential for misleading comparisons of the Company's
operating results to its competitors.
Item    9.01    Financial
Statements and Exhibits.
(c)
Exhibits
See Exhibit Index attached to this Current Report on Form 8-K.
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
MILLENNIUM PHARMACEUTICALS, INC.
(Registrant)
Date: January 5, 2006
By
/s/  MARSHA H. FANUCCI
Marsha H. Fanucci
Senior Vice President and Chief Financial Officer
4
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release of Millennium Pharmaceuticals, Inc. dated January 5, 2006
5